Oncolytic Virus Service

Oncolytic Virus Service

As a globally oriented leader in gene therapy field, Baseceuticals offers oncolytic virus services with high quality based on our excellent and mature platform. Depending on the top-of-the-line technologies and state-of-the-art equipment, our experienced technical team has succeeded in numerous oncolytic virus projects, including oncolytic virus construction, engineering and validation. At Baseceuticals, we will put forward the best strategies for your projects to meet the requirements after communication and analysis of the specific situation. Our scientists will work closely with you to help you drive the project forward.

The oncolytic virus (OV) is a group of tumor-killing virus with replication ability, reproducing effectively in cancer cells without damaging healthy cells. Oncolytic viruses can be separated into two main groups according to the development, namely natural viruses and genetically modified viruses. Among them, natural viruses include wide type and naturally variant strains of weak virus. The ability to produce virions quickly and genetically engineer additional genes that promote antitumor immunity, increase tumor cell susceptibility, and improve patient safety, are main advantages of oncolytic viruses.

The mechanism of oncolytic virus action is to selectively replicate in and destroy tumor cells. At the same time, it can stimulate the immune response to attract more immune cells to destroy residual cancer cells continuously. The following is a summary of the immune response caused by oncolytic virus-infected organisms. The virus has a strong stimulating result on the immune cells infiltrating the tumor, significantly changing the microenvironment of the tumor. Tumor cells that infected by viruses express “danger signals” (such as cytokines), inducing outside immune cells to infiltrate the tumor and activate nonspecific immune cells. Non-specific immune cells phagocytize tumor proteins that released by OV-lysed tumor cells, and some tumor-specific antigens could be expressed by antigen presenting cells, inducing T cells to attack uninfected tumor cells.

Fig.1  Oncolytic viruses and their possible function in tumor therapyFig.1 Oncolytic viruses and their possible function in tumor therapy

Nowadays, oncolytic viruses have been used in clinical trials for treatment and there is an oncolytic virus product T-VEC that has been approved by FDA. Oncolytic virotherapy has been regarded as a promising and effective approach for cancer therapeutics that is easier to destroy tumor cells compared with radiation therapy and chemotherapy.

The following is the features of oncolytic virotherapy:

  • Specificity for target cancer
  • High-efficiency to kill infected cells
  • Safety to avoid adverse reactions

At present, adenoviruses, vaccinia viruses, herpes viruses, reoviruses and coxsackieviruses are the widely studied oncolytic viruses. The table below lists some commonly oncolytic viruses and related indications.

Virus TypeVirus NameClinical StageIndications


Onyx-0152Head and neck cancer, pancreatic cancer, ovarian cancer, colon cancer, liver cancer, glioma
DNX-24012Ovarian cancer, glioma
Colo-Adl2Colon cancer, lung cancer, mesothelioma, breast cancer, prostate
Oncos-1022Colorectal cancer, prostate cancer, melanoma, ovarian cancer
ProstAtak3Pancreatic cancer, lung cancer, mesothelioma, breast cancer, prostate cancer,
CG00703Bladder Cancer
Vaccinia virusPexa-Vec3Melanoma, liver cancer, colorectal cancer, breast cancer
GL-ONC12Lung cancer, head and neck cancer, mesothelioma
Herpes virusHF102Melanoma, pancreatic cancer
HSV17162Melanoma, liver cancer, pleural cancer, malignant glioma
T-VECFDA approvedMelanoma
ReovirusReolysin3Head and neck cancer, malignant glioma, prostate cancer, colorectal cancer, non-small cell lung cancer, breast cancer
CoxsackievirusCavatak2Melanoma, solid tumor, non-small cell lung cancer

Oncolytic Virus Service Includes

  • Oncolytic virus construction
  • Oncolytic virus engineering
  • Oncolytic virus validation
  • Disease-specific oncolytic virotherapy development

Advantages of Oncolytic Virus Service in Baseceuticals

  • Free consultation and prompt response
  • Years of experience in oncolytic virus service
  • Leading-edge equipment and best-in-class technologies
  • Fast turnaround time with reliable results
  • Multiple oncolytic virus types are available
  • Reasonable price with high quality services
  • Customize services with feasible proposals to meet the specific requirements

Baseceuticals is the division of Creative Biogene that provides oncolytic virus services with high-quality. Our technical research team is specializing in developing efficient systems and procedures in the projects related to oncolytic virus. The service begins with free communication followed by feasible proposals to meet your specific need. We have confidence to provide the best oncolytic virus service with affordable price and reliable results. If you have questions about the oncolytic virus service, please do not hesitate to contact us at .


  1. Moehler, M., Goepfert, K., Heinrich, B., Breitbach, C. J., Delic, M., Galle, P. R., Rommelaere, J.. (2014). Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1. Frontiers in Oncology, 4:92.
For research use only. Not intended for any clinical use.

Get in Touch

Please contact us if you have questions about our company, our products, or general enquiries.

Please use the form below.